Occult retinal neovascularization following intravitreal bevacizumab and laser treatment for retinopathy of prematurity

BMC Pediatr. 2024 May 4;24(1):301. doi: 10.1186/s12887-024-04784-1.

Abstract

Background: We present a patient with retinopathy of prematurity (ROP) who developed worsening plus disease after complete regression of stage 3 ROP. The use of fundus fluorescein angiography (FFA) aided the visualization of occult neovascularization that caused the disease progression.

Case presentation: The patient was at high risk for ROP due to low birth weight of 690 g and gestational age of 25 weeks. After the diagnosis of stage 3 ROP in zone I without plus disease, she was treated initially with bilateral intravitreal bevacizumab (IVB) and followed by laser photocoagulation 5 weeks later. Despite the resolution of ROP stage, the plus disease worsened. Neither systemic risk factors nor skip laser areas were observed. Hence, FFA was performed and subsequently identified occult neovascularization with active leakage. Additional IVB and laser treatment in the capillary dropout area inside vascularized retina were added. The plus disease improved but mild arteriolar tortuosity persisted.

Conclusions: Worsening of plus disease after completion of laser ablation and IVB with complete regression of stage 3 ROP is rare. Systemic risk factors such as continuous oxygen therapy and cardiovascular disease should be ruled out. FFA aided in identifying occult neovascularization and prompted further treatment.

Keywords: Occult neovascularization; Plus disease; Retinopathy of prematurity.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors* / administration & dosage
  • Angiogenesis Inhibitors* / therapeutic use
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bevacizumab* / administration & dosage
  • Bevacizumab* / therapeutic use
  • Combined Modality Therapy
  • Female
  • Fluorescein Angiography*
  • Humans
  • Infant, Newborn
  • Intravitreal Injections*
  • Laser Coagulation* / methods
  • Retinal Neovascularization* / drug therapy
  • Retinal Neovascularization* / etiology
  • Retinopathy of Prematurity*

Substances

  • Bevacizumab
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized